62P PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A pooled analysis of three randomized trials

Y Chen,X Meng,L Xing,H Zhao,L Jiang,L Zhang,C Zhou,J Yu

doi:10.1016/j.annonc.2021.10.080

62P PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A pooled analysis of three randomized trials

Y Chen, X Meng + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.080

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
License type: publisher-specific-oa

Affiliation: Shandong Tumor Hospital, Shandong First Medical University, Sun Yat-sen University Cancer Center, Shanghai Pulmonary Hospital

#Non-squamous Non-small Cell Lung Cancer #Advanced Non-squamous Non-small Cell Lung + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To date, none of randomized trials aim to compare the efficacy of programmed death 1 (PD-1) inhibitor plus chemotherapy and bevacizumab plus chemotherapy as first-line treatment for non-squamous non-small cell lung cancer (NSCLC). This analysis pooled prospective data to compare the survival benefits of the two regimens for advanced NSCLC without targetable genetic mutations.

Full Text